TWI623522B - 1-[間-甲醯胺基(雜)芳基-甲基]-雜環-甲醯胺衍生物 - Google Patents
1-[間-甲醯胺基(雜)芳基-甲基]-雜環-甲醯胺衍生物 Download PDFInfo
- Publication number
- TWI623522B TWI623522B TW102122237A TW102122237A TWI623522B TW I623522 B TWI623522 B TW I623522B TW 102122237 A TW102122237 A TW 102122237A TW 102122237 A TW102122237 A TW 102122237A TW I623522 B TWI623522 B TW I623522B
- Authority
- TW
- Taiwan
- Prior art keywords
- carboxylic acid
- phenyl
- hexahydropyridine
- benzyl
- ylmethyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 220
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 13
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 6
- -1 heteroaryl pyridine Chemical compound 0.000 claims description 610
- 125000000217 alkyl group Chemical group 0.000 claims description 166
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 claims description 87
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 81
- OKBHXGBLXDNJJD-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(C(F)(F)F)=N1 OKBHXGBLXDNJJD-UHFFFAOYSA-N 0.000 claims description 80
- 125000001424 substituent group Chemical group 0.000 claims description 75
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims description 62
- 229910052736 halogen Inorganic materials 0.000 claims description 60
- 150000002367 halogens Chemical class 0.000 claims description 60
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 59
- 229910052739 hydrogen Inorganic materials 0.000 claims description 57
- 239000001257 hydrogen Substances 0.000 claims description 57
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 56
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 55
- 125000003118 aryl group Chemical group 0.000 claims description 43
- 229910052757 nitrogen Inorganic materials 0.000 claims description 42
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 40
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 37
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 37
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 36
- 125000004432 carbon atom Chemical group C* 0.000 claims description 35
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 35
- 239000011570 nicotinamide Substances 0.000 claims description 34
- 229960003966 nicotinamide Drugs 0.000 claims description 34
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 33
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 32
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 31
- 229910052731 fluorine Inorganic materials 0.000 claims description 31
- 239000011737 fluorine Substances 0.000 claims description 31
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 30
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
- 229920006395 saturated elastomer Polymers 0.000 claims description 26
- 125000001072 heteroaryl group Chemical group 0.000 claims description 25
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims description 24
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 22
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 22
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 22
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 21
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 20
- 125000004429 atom Chemical group 0.000 claims description 19
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 19
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- 239000001301 oxygen Substances 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 17
- 239000004593 Epoxy Substances 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 15
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 15
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 14
- 150000002431 hydrogen Chemical group 0.000 claims description 13
- 125000002757 morpholinyl group Chemical group 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 12
- 102000005962 receptors Human genes 0.000 claims description 12
- 108020003175 receptors Proteins 0.000 claims description 12
- 125000003725 azepanyl group Chemical group 0.000 claims description 11
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 11
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 11
- NJHGVAYLDHROPT-UHFFFAOYSA-N 5-(trifluoromethyl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(C(F)(F)F)C=N1 NJHGVAYLDHROPT-UHFFFAOYSA-N 0.000 claims description 10
- JTKFIIQGMVKDNZ-UHFFFAOYSA-N 5-fluoropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(F)C=N1 JTKFIIQGMVKDNZ-UHFFFAOYSA-N 0.000 claims description 10
- 150000001204 N-oxides Chemical class 0.000 claims description 10
- 125000002947 alkylene group Chemical group 0.000 claims description 10
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
- GJLOKYIYZIOIPN-UHFFFAOYSA-N 5-chloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(Cl)C=N1 GJLOKYIYZIOIPN-UHFFFAOYSA-N 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 9
- 206010016654 Fibrosis Diseases 0.000 claims description 9
- MSZJEPVVQWJCIF-UHFFFAOYSA-N butylazanide Chemical compound CCCC[NH-] MSZJEPVVQWJCIF-UHFFFAOYSA-N 0.000 claims description 9
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 230000004761 fibrosis Effects 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims description 7
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 7
- BPRWTROIQXSSOC-UHFFFAOYSA-N 4-(trifluoromethyl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC(C(F)(F)F)=CC=N1 BPRWTROIQXSSOC-UHFFFAOYSA-N 0.000 claims description 6
- LTUUGSGSUZRPRV-UHFFFAOYSA-N 6-methylpyridine-2-carboxylic acid Chemical compound CC1=CC=CC(C(O)=O)=N1 LTUUGSGSUZRPRV-UHFFFAOYSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- YPOXGDJGKBXRFP-UHFFFAOYSA-N pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 6
- 206010052779 Transplant rejections Diseases 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 claims description 5
- 238000002054 transplantation Methods 0.000 claims description 5
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 4
- NNMYRMGMVLMQAY-UHFFFAOYSA-N 4-chloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC(Cl)=CC=N1 NNMYRMGMVLMQAY-UHFFFAOYSA-N 0.000 claims description 4
- WDJARUKOMOGTHA-UHFFFAOYSA-N 5-aminopyridine-2-carboxylic acid Chemical compound NC1=CC=C(C(O)=O)N=C1 WDJARUKOMOGTHA-UHFFFAOYSA-N 0.000 claims description 4
- ISWYPIVHUPCJGU-UHFFFAOYSA-N 5-chloro-3-fluoropyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC=C(Cl)C=C1F ISWYPIVHUPCJGU-UHFFFAOYSA-N 0.000 claims description 4
- RBYJWCRKFLGNDB-UHFFFAOYSA-N 5-methylpyrazine-2-carboxylic acid Chemical compound CC1=CN=C(C(O)=O)C=N1 RBYJWCRKFLGNDB-UHFFFAOYSA-N 0.000 claims description 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 4
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 claims description 4
- KMAKOBLIOCQGJP-UHFFFAOYSA-N indole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CNC2=C1 KMAKOBLIOCQGJP-UHFFFAOYSA-N 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- 230000037361 pathway Effects 0.000 claims description 4
- NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 claims description 4
- VXGYRCVTBHVXMZ-UHFFFAOYSA-N quinoline-6-carboxylic acid Chemical compound N1=CC=CC2=CC(C(=O)O)=CC=C21 VXGYRCVTBHVXMZ-UHFFFAOYSA-N 0.000 claims description 4
- DLRDXTGHDMVWQQ-UHFFFAOYSA-N 1-[[3-[(5-methylpyridine-3-carbonyl)amino]phenyl]methyl]azepane-4-carboxylic acid Chemical compound CC1=CN=CC(C(=O)NC=2C=C(CN3CCC(CCC3)C(O)=O)C=CC=2)=C1 DLRDXTGHDMVWQQ-UHFFFAOYSA-N 0.000 claims description 3
- KSPOBZHOVRJBHT-UHFFFAOYSA-N N-[3-[1-[4-(pyrrolidine-1-carbonyl)piperidin-1-yl]ethyl]phenyl]benzamide Chemical compound C=1C=CC(NC(=O)C=2C=CC=CC=2)=CC=1C(C)N(CC1)CCC1C(=O)N1CCCC1 KSPOBZHOVRJBHT-UHFFFAOYSA-N 0.000 claims description 3
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 claims description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 3
- QKYWADPCTHTJHQ-UHFFFAOYSA-N n,2-dimethylpropan-1-amine Chemical compound CNCC(C)C QKYWADPCTHTJHQ-UHFFFAOYSA-N 0.000 claims description 3
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims description 3
- GYLDXXLJMRTVSS-UHFFFAOYSA-N n-butylacetamide Chemical compound CCCCNC(C)=O GYLDXXLJMRTVSS-UHFFFAOYSA-N 0.000 claims description 3
- YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 claims description 2
- JRZGPXSSNPTNMA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=CC=C2C(N)CCCC2=C1 JRZGPXSSNPTNMA-UHFFFAOYSA-N 0.000 claims description 2
- OUIALVLMUYKKKS-UHFFFAOYSA-N 1,2,3-benzothiadiazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2SN=NC2=C1 OUIALVLMUYKKKS-UHFFFAOYSA-N 0.000 claims description 2
- DMPZJACLHDWUFS-UHFFFAOYSA-N 1,3-benzothiazole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2N=CSC2=C1 DMPZJACLHDWUFS-UHFFFAOYSA-N 0.000 claims description 2
- OZZMWXQJCJUCEJ-UHFFFAOYSA-N 1,6-naphthyridine-2-carboxylic acid Chemical compound C1=NC=CC2=NC(C(=O)O)=CC=C21 OZZMWXQJCJUCEJ-UHFFFAOYSA-N 0.000 claims description 2
- VTCQMWNBVKOUQF-UHFFFAOYSA-N 1-[[3-(cycloheptanecarbonylamino)phenyl]methyl]-N-cyclohexylpiperidine-4-carboxamide Chemical compound C1CN(CC=2C=C(NC(=O)C3CCCCCC3)C=CC=2)CCC1C(=O)NC1CCCCC1 VTCQMWNBVKOUQF-UHFFFAOYSA-N 0.000 claims description 2
- XFRBPLHZOIAUGT-UHFFFAOYSA-N 1-[[3-[(5-chlorothiophene-2-carbonyl)amino]phenyl]methyl]-n-cyclohexylpiperidine-4-carboxamide Chemical compound S1C(Cl)=CC=C1C(=O)NC1=CC=CC(CN2CCC(CC2)C(=O)NC2CCCCC2)=C1 XFRBPLHZOIAUGT-UHFFFAOYSA-N 0.000 claims description 2
- UFIYRLCEYHWOND-RZTXVSJASA-N 1-[[3-[[(1S,2R,4R)-bicyclo[2.2.1]heptane-2-carbonyl]amino]phenyl]methyl]-N-cyclohexylpiperidine-4-carboxamide Chemical compound O=C([C@H]1[C@@]2([H])CC[C@](C2)(C1)[H])NC(C=1)=CC=CC=1CN(CC1)CCC1C(=O)NC1CCCCC1 UFIYRLCEYHWOND-RZTXVSJASA-N 0.000 claims description 2
- HARJXUSQQRGVHK-UHFFFAOYSA-N 1-[[3-[[2-(2-chloro-4-fluorophenyl)acetyl]amino]phenyl]methyl]pyrrolidine-3-carboxylic acid Chemical compound OC(=O)C1CCN(Cc2cccc(NC(=O)Cc3ccc(F)cc3Cl)c2)C1 HARJXUSQQRGVHK-UHFFFAOYSA-N 0.000 claims description 2
- XMNRYCLMXUYTCH-UHFFFAOYSA-N 1-[[3-[[2-(3-chlorophenyl)acetyl]amino]phenyl]methyl]-N-cyclohexylpiperidine-4-carboxamide Chemical compound ClC1=CC=CC(CC(=O)NC=2C=C(CN3CCC(CC3)C(=O)NC3CCCCC3)C=CC=2)=C1 XMNRYCLMXUYTCH-UHFFFAOYSA-N 0.000 claims description 2
- OJTABMQHOSLGHU-UHFFFAOYSA-N 1-[[4-chloro-3-[(2-phenylcyclopropanecarbonyl)amino]phenyl]methyl]-N-cyclohexylpiperidine-4-carboxamide Chemical compound C1=C(NC(=O)C2C(C2)C=2C=CC=CC=2)C(Cl)=CC=C1CN(CC1)CCC1C(=O)NC1CCCCC1 OJTABMQHOSLGHU-UHFFFAOYSA-N 0.000 claims description 2
- HOHMBIGNVLUNTN-UHFFFAOYSA-N 1-[[4-chloro-3-[(5-methylthiophene-2-carbonyl)amino]phenyl]methyl]-N-cyclohexylpiperidine-4-carboxamide Chemical compound S1C(C)=CC=C1C(=O)NC1=CC(CN2CCC(CC2)C(=O)NC2CCCCC2)=CC=C1Cl HOHMBIGNVLUNTN-UHFFFAOYSA-N 0.000 claims description 2
- BHXVYTQDWMQVBI-UHFFFAOYSA-N 1h-indazole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=NNC2=C1 BHXVYTQDWMQVBI-UHFFFAOYSA-N 0.000 claims description 2
- SINFYKZXNIJIEU-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine-5-carboxylic acid Chemical compound OC(=O)C1=CN=C2NC=CC2=C1 SINFYKZXNIJIEU-UHFFFAOYSA-N 0.000 claims description 2
- XDIAMRVROCPPBK-UHFFFAOYSA-N 2,2-dimethylpropan-1-amine Chemical compound CC(C)(C)CN XDIAMRVROCPPBK-UHFFFAOYSA-N 0.000 claims description 2
- RXHBTEVUVWXEBO-UHFFFAOYSA-N 2,3-dihydro-1h-indole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)CNC2=C1 RXHBTEVUVWXEBO-UHFFFAOYSA-N 0.000 claims description 2
- FQUBTCRHHXVCTJ-UHFFFAOYSA-N 2-(dimethylamino)-6-methylpyrimidine-4-carboxylic acid Chemical compound CN(C)C1=NC(C)=CC(C(O)=O)=N1 FQUBTCRHHXVCTJ-UHFFFAOYSA-N 0.000 claims description 2
- CDBDBWCUGHXFTN-UHFFFAOYSA-N 2-methylpyrimidine-4-carboxylic acid Chemical compound CC1=NC=CC(C(O)=O)=N1 CDBDBWCUGHXFTN-UHFFFAOYSA-N 0.000 claims description 2
- KBDIRPOTVAODSA-UHFFFAOYSA-N 3-bromopyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CC=C1Br KBDIRPOTVAODSA-UHFFFAOYSA-N 0.000 claims description 2
- LMHIBYREWJHKNZ-UHFFFAOYSA-N 3-methylpyridine-2-carboxylic acid Chemical compound CC1=CC=CN=C1C(O)=O LMHIBYREWJHKNZ-UHFFFAOYSA-N 0.000 claims description 2
- DYOKWPWMTZHTPS-UHFFFAOYSA-N 4,6-dimethylpyridine-2-carboxylic acid Chemical compound CC1=CC(C)=NC(C(O)=O)=C1 DYOKWPWMTZHTPS-UHFFFAOYSA-N 0.000 claims description 2
- BLNVISNJTIRAHF-UHFFFAOYSA-N 4-chlorobenzamide Chemical compound NC(=O)C1=CC=C(Cl)C=C1 BLNVISNJTIRAHF-UHFFFAOYSA-N 0.000 claims description 2
- CMMURVLHXMNTHY-UHFFFAOYSA-N 4-methylpyridine-2-carboxylic acid Chemical compound CC1=CC=NC(C(O)=O)=C1 CMMURVLHXMNTHY-UHFFFAOYSA-N 0.000 claims description 2
- XPDRNYPDWRORIX-UHFFFAOYSA-N 5-methyl-N-[3-[[4-(piperidine-1-carbonyl)piperidin-1-yl]methyl]phenyl]pyridine-3-carboxamide Chemical compound CC1=CN=CC(C(=O)NC=2C=C(CN3CCC(CC3)C(=O)N3CCCCC3)C=CC=2)=C1 XPDRNYPDWRORIX-UHFFFAOYSA-N 0.000 claims description 2
- ACLFTMQROMOTLA-UHFFFAOYSA-N 5-pyrrolidin-1-ylpyridine-2-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC=C1N1CCCC1 ACLFTMQROMOTLA-UHFFFAOYSA-N 0.000 claims description 2
- XURXQNUIGWHWHU-UHFFFAOYSA-N 6-bromopyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(Br)=N1 XURXQNUIGWHWHU-UHFFFAOYSA-N 0.000 claims description 2
- ZLKMOIHCHCMSFW-UHFFFAOYSA-N 6-chloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(Cl)=N1 ZLKMOIHCHCMSFW-UHFFFAOYSA-N 0.000 claims description 2
- UFGQWTWQNIGAEB-UHFFFAOYSA-N 7-chloroquinoline-3-carboxylic acid Chemical compound C1=C(Cl)C=CC2=CC(C(=O)O)=CN=C21 UFGQWTWQNIGAEB-UHFFFAOYSA-N 0.000 claims description 2
- IBKMOKTZCWPLMZ-UHFFFAOYSA-N N-(cyclopropylmethyl)-1-[[3-[[6-(trifluoromethyl)pyridine-2-carbonyl]amino]phenyl]methyl]azepane-4-carboxamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)NC=2C=C(CN3CCC(CCC3)C(=O)NCC3CC3)C=CC=2)=N1 IBKMOKTZCWPLMZ-UHFFFAOYSA-N 0.000 claims description 2
- ZQAGGJMGNNCDQB-UHFFFAOYSA-N N-[3-[[4-(2,2-dimethylpyrrolidine-1-carbonyl)piperidin-1-yl]methyl]phenyl]-5-methylpyridine-3-carboxamide Chemical compound CC1=CN=CC(C(=O)NC=2C=C(CN3CCC(CC3)C(=O)N3C(CCC3)(C)C)C=CC=2)=C1 ZQAGGJMGNNCDQB-UHFFFAOYSA-N 0.000 claims description 2
- SXVKQKWXRCFXOE-UHFFFAOYSA-N N-[3-[[4-(azepane-1-carbonyl)piperidin-1-yl]methyl]phenyl]-5-methylpyridine-3-carboxamide Chemical compound CC1=CN=CC(C(=O)NC=2C=C(CN3CCC(CC3)C(=O)N3CCCCCC3)C=CC=2)=C1 SXVKQKWXRCFXOE-UHFFFAOYSA-N 0.000 claims description 2
- FJLKPARHYZWESS-UHFFFAOYSA-N N-[3-[[4-(cyclohexylcarbamoyl)piperidin-1-yl]methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound C1CN(CC=2C=C(NC(=O)C=3ON=CC=3)C=CC=2)CCC1C(=O)NC1CCCCC1 FJLKPARHYZWESS-UHFFFAOYSA-N 0.000 claims description 2
- WIZXULXYVGVFEO-UHFFFAOYSA-N N-cyclohexyl-1-[1-[3-[[2-[3-(trifluoromethyl)phenyl]acetyl]amino]phenyl]ethyl]piperidine-4-carboxamide Chemical compound C=1C=CC(NC(=O)CC=2C=C(C=CC=2)C(F)(F)F)=CC=1C(C)N(CC1)CCC1C(=O)NC1CCCCC1 WIZXULXYVGVFEO-UHFFFAOYSA-N 0.000 claims description 2
- OFCHGAWKJNGFRT-UHFFFAOYSA-N N-cyclohexyl-1-[[3-(1H-imidazole-2-carbonylamino)phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CN(CC=2C=C(NC(=O)C=3NC=CN=3)C=CC=2)CCC1C(=O)NC1CCCCC1 OFCHGAWKJNGFRT-UHFFFAOYSA-N 0.000 claims description 2
- CIJSUDVKQRGPCF-UHFFFAOYSA-N N-cyclohexyl-1-[[3-(3-phenylpropanoylamino)phenyl]methyl]piperidine-4-carboxamide Chemical compound C=1C=CC(CN2CCC(CC2)C(=O)NC2CCCCC2)=CC=1NC(=O)CCC1=CC=CC=C1 CIJSUDVKQRGPCF-UHFFFAOYSA-N 0.000 claims description 2
- AMCJIVLDCCMEHT-UHFFFAOYSA-N N-cyclohexyl-1-[[3-(naphthalene-2-carbonylamino)phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CN(CC=2C=C(NC(=O)C=3C=C4C=CC=CC4=CC=3)C=CC=2)CCC1C(=O)NC1CCCCC1 AMCJIVLDCCMEHT-UHFFFAOYSA-N 0.000 claims description 2
- YDLISZOJJJELQQ-UHFFFAOYSA-N N-cyclohexyl-1-[[3-(thiophene-2-carbonylamino)phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CN(CC=2C=C(NC(=O)C=3SC=CC=3)C=CC=2)CCC1C(=O)NC1CCCCC1 YDLISZOJJJELQQ-UHFFFAOYSA-N 0.000 claims description 2
- BWXVZHHYROKFSK-UHFFFAOYSA-N N-cyclohexyl-1-[[3-[(3-methyl-2-phenylbutanoyl)amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C=1C=CC=CC=1C(C(C)C)C(=O)NC(C=1)=CC=CC=1CN(CC1)CCC1C(=O)NC1CCCCC1 BWXVZHHYROKFSK-UHFFFAOYSA-N 0.000 claims description 2
- GERWIYXWCQFDOT-UHFFFAOYSA-N N-cyclohexyl-1-[[3-[[2-(2,3-dihydro-1H-inden-2-yl)acetyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C1C2=CC=CC=C2CC1CC(=O)NC(C=1)=CC=CC=1CN(CC1)CCC1C(=O)NC1CCCCC1 GERWIYXWCQFDOT-UHFFFAOYSA-N 0.000 claims description 2
- OAENTWNJBDZOPO-UHFFFAOYSA-N N-cyclohexyl-1-[[3-[[2-(3-methoxyphenyl)acetyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound COC1=CC=CC(CC(=O)NC=2C=C(CN3CCC(CC3)C(=O)NC3CCCCC3)C=CC=2)=C1 OAENTWNJBDZOPO-UHFFFAOYSA-N 0.000 claims description 2
- SXJFWFYNKDJQPF-UHFFFAOYSA-N N-cyclohexyl-1-[[3-[[5-methyl-4-(2-methylpropyl)thiophene-2-carbonyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound S1C(C)=C(CC(C)C)C=C1C(=O)NC1=CC=CC(CN2CCC(CC2)C(=O)NC2CCCCC2)=C1 SXJFWFYNKDJQPF-UHFFFAOYSA-N 0.000 claims description 2
- OZPHSJTZAPUYAN-UHFFFAOYSA-N N-tert-butyl-1-[[3-[(2,2,3,3-tetramethylcyclopropanecarbonyl)amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)C2C(C2(C)C)(C)C)=C1 OZPHSJTZAPUYAN-UHFFFAOYSA-N 0.000 claims description 2
- HEXAVTUJSUQWJO-UHFFFAOYSA-N N-tert-butyl-1-[[3-[(2,2-dimethylcyclopropanecarbonyl)amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)C2C(C2)(C)C)=C1 HEXAVTUJSUQWJO-UHFFFAOYSA-N 0.000 claims description 2
- YWKGICVYAZZSDI-UHFFFAOYSA-N N-tert-butyl-1-[[3-[(2-methyl-2-phenylpropanoyl)amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)C(C)(C)C=2C=CC=CC=2)=C1 YWKGICVYAZZSDI-UHFFFAOYSA-N 0.000 claims description 2
- MCMXVCGQDGDFBQ-UHFFFAOYSA-N N-tert-butyl-1-[[3-[[1-(4-chlorophenyl)cyclopropanecarbonyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)C2(CC2)C=2C=CC(Cl)=CC=2)=C1 MCMXVCGQDGDFBQ-UHFFFAOYSA-N 0.000 claims description 2
- QYHMGVQXALKVGU-UHFFFAOYSA-N N-tert-butyl-1-[[3-[[2-(2,3-dichloro-6-fluorophenyl)acetyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)CC=2C(=C(Cl)C=CC=2F)Cl)=C1 QYHMGVQXALKVGU-UHFFFAOYSA-N 0.000 claims description 2
- LGONIGYPQOACRH-UHFFFAOYSA-N N-tert-butyl-1-[[3-[[2-(2-chloro-3,6-difluorophenyl)acetyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)CC=2C(=C(F)C=CC=2F)Cl)=C1 LGONIGYPQOACRH-UHFFFAOYSA-N 0.000 claims description 2
- SLACPBXEXJJMML-UHFFFAOYSA-N N-tert-butyl-1-[[3-[[2-(2-chloro-6-fluorophenyl)acetyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)CC=2C(=CC=CC=2F)Cl)=C1 SLACPBXEXJJMML-UHFFFAOYSA-N 0.000 claims description 2
- ZVNAANFBWGYEBY-UHFFFAOYSA-N N-tert-butyl-1-[[3-[[2-[2-chloro-3-(trifluoromethyl)phenyl]acetyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)CC=2C(=C(C=CC=2)C(F)(F)F)Cl)=C1 ZVNAANFBWGYEBY-UHFFFAOYSA-N 0.000 claims description 2
- SSHRCLUWIJHWAF-UHFFFAOYSA-N N-tert-butyl-1-[[4-[[2-(2-chlorophenyl)acetyl]amino]thiophen-2-yl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC(NC(=O)CC=2C(=CC=CC=2)Cl)=CS1 SSHRCLUWIJHWAF-UHFFFAOYSA-N 0.000 claims description 2
- OFGVVAYTPSOPNY-UHFFFAOYSA-N OC(=O)C1CCCN(Cc2cccc(NC(=O)c3cccc(n3)C(F)(F)F)c2)CC1 Chemical compound OC(=O)C1CCCN(Cc2cccc(NC(=O)c3cccc(n3)C(F)(F)F)c2)CC1 OFGVVAYTPSOPNY-UHFFFAOYSA-N 0.000 claims description 2
- HSPUGFHFJURQGZ-UHFFFAOYSA-N OC(=O)C1CCN(Cc2cccc(NC(=O)Cc3ccc(F)cc3Cl)c2)CC1 Chemical compound OC(=O)C1CCN(Cc2cccc(NC(=O)Cc3ccc(F)cc3Cl)c2)CC1 HSPUGFHFJURQGZ-UHFFFAOYSA-N 0.000 claims description 2
- OFGVVAYTPSOPNY-HNNXBMFYSA-N OC(=O)[C@H]1CCCN(Cc2cccc(NC(=O)c3cccc(n3)C(F)(F)F)c2)CC1 Chemical compound OC(=O)[C@H]1CCCN(Cc2cccc(NC(=O)c3cccc(n3)C(F)(F)F)c2)CC1 OFGVVAYTPSOPNY-HNNXBMFYSA-N 0.000 claims description 2
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 claims description 2
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 claims description 2
- YKNZTUQUXUXTLE-UHFFFAOYSA-N [3-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=CC(C(F)(F)F)=C1 YKNZTUQUXUXTLE-UHFFFAOYSA-N 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- XAAKCCMYRKZRAK-UHFFFAOYSA-N isoquinoline-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=NC=CC2=C1 XAAKCCMYRKZRAK-UHFFFAOYSA-N 0.000 claims description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
- KRZCGVNZELVVOB-UHFFFAOYSA-N n-cyclohexyl-1-[[3-(naphthalene-1-carbonylamino)phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CN(CC=2C=C(NC(=O)C=3C4=CC=CC=C4C=CC=3)C=CC=2)CCC1C(=O)NC1CCCCC1 KRZCGVNZELVVOB-UHFFFAOYSA-N 0.000 claims description 2
- RICFPYPDGDXXBB-UHFFFAOYSA-N n-cyclohexyl-1-[[3-[[2-(2-methoxyphenyl)acetyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound COC1=CC=CC=C1CC(=O)NC1=CC=CC(CN2CCC(CC2)C(=O)NC2CCCCC2)=C1 RICFPYPDGDXXBB-UHFFFAOYSA-N 0.000 claims description 2
- BEFFRMBGYHPHKZ-UHFFFAOYSA-N n-tert-butyl-1-[[3-(2,3-dihydro-1-benzofuran-3-carbonylamino)phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)C2C3=CC=CC=C3OC2)=C1 BEFFRMBGYHPHKZ-UHFFFAOYSA-N 0.000 claims description 2
- WQJMLWPPEPVWRT-UHFFFAOYSA-N n-tert-butyl-1-[[3-(2,3-dihydro-1h-indene-1-carbonylamino)phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)C2C3=CC=CC=C3CC2)=C1 WQJMLWPPEPVWRT-UHFFFAOYSA-N 0.000 claims description 2
- WGDZZEMXCRVIRP-UHFFFAOYSA-N n-tert-butyl-1-[[3-[(5-methylpyridine-3-carbonyl)amino]phenyl]methyl]azepane-4-carboxamide Chemical compound CC1=CN=CC(C(=O)NC=2C=C(CN3CCC(CCC3)C(=O)NC(C)(C)C)C=CC=2)=C1 WGDZZEMXCRVIRP-UHFFFAOYSA-N 0.000 claims description 2
- BYGDQRVCBGFQLZ-UHFFFAOYSA-N n-tert-butyl-1-[[3-[[2-(2,3-dichlorophenyl)acetyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)CC=2C(=C(Cl)C=CC=2)Cl)=C1 BYGDQRVCBGFQLZ-UHFFFAOYSA-N 0.000 claims description 2
- RYJGOOFWXBVDKG-UHFFFAOYSA-N n-tert-butyl-1-[[3-[[2-(2-chlorophenyl)acetyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)CC=2C(=CC=CC=2)Cl)=C1 RYJGOOFWXBVDKG-UHFFFAOYSA-N 0.000 claims description 2
- PEWRQYYEODCVSW-UHFFFAOYSA-N n-tert-butyl-1-[[3-[[2-(4-chlorophenyl)-2-methylpropanoyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)C(C)(C)C=2C=CC(Cl)=CC=2)=C1 PEWRQYYEODCVSW-UHFFFAOYSA-N 0.000 claims description 2
- AAUYXQDVSOCYJB-UHFFFAOYSA-N n-tert-butyl-1-[[3-[[2-[2,6-dichloro-3-(trifluoromethyl)phenyl]acetyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)CC=2C(=C(C=CC=2Cl)C(F)(F)F)Cl)=C1 AAUYXQDVSOCYJB-UHFFFAOYSA-N 0.000 claims description 2
- 229960002715 nicotine Drugs 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- RUUOPSRRIKJHNH-UHFFFAOYSA-N pyridazine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=N1 RUUOPSRRIKJHNH-UHFFFAOYSA-N 0.000 claims description 2
- ZFCHNZDUMIOWFV-UHFFFAOYSA-N pyrimidine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CC=N1 ZFCHNZDUMIOWFV-UHFFFAOYSA-N 0.000 claims description 2
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 claims description 2
- UPUZGXILYFKSGE-UHFFFAOYSA-N quinoxaline-2-carboxylic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CN=C21 UPUZGXILYFKSGE-UHFFFAOYSA-N 0.000 claims description 2
- VSRBKQFNFZQRBM-UHFFFAOYSA-N tuaminoheptane Chemical compound CCCCCC(C)N VSRBKQFNFZQRBM-UHFFFAOYSA-N 0.000 claims description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- RDRCCJPEJDWSRJ-UHFFFAOYSA-N pyridine;1h-pyrrole Chemical compound C=1C=CNC=1.C1=CC=NC=C1 RDRCCJPEJDWSRJ-UHFFFAOYSA-N 0.000 claims 2
- CJAAPVQEZPAQNI-UHFFFAOYSA-N (2-methylphenyl)methanamine Chemical compound CC1=CC=CC=C1CN CJAAPVQEZPAQNI-UHFFFAOYSA-N 0.000 claims 1
- RGXUCUWVGKLACF-UHFFFAOYSA-N (3-methylphenyl)methanamine Chemical compound CC1=CC=CC(CN)=C1 RGXUCUWVGKLACF-UHFFFAOYSA-N 0.000 claims 1
- PQXWYQZQCWWMDQ-UHFFFAOYSA-N (4-fluoro-3-methylphenyl)methanamine Chemical compound CC1=CC(CN)=CC=C1F PQXWYQZQCWWMDQ-UHFFFAOYSA-N 0.000 claims 1
- JOZSYOPADROCMP-UHFFFAOYSA-N 1,3-thiazol-2-ylmethanamine Chemical compound NCC1=NC=CS1 JOZSYOPADROCMP-UHFFFAOYSA-N 0.000 claims 1
- GUDRCTXILCXKRP-UHFFFAOYSA-N 1-[[3-(1-benzofuran-3-carbonylamino)phenyl]methyl]-n-cyclohexylpiperidine-4-carboxamide Chemical compound C1CN(CC=2C=C(NC(=O)C=3C4=CC=CC=C4OC=3)C=CC=2)CCC1C(=O)NC1CCCCC1 GUDRCTXILCXKRP-UHFFFAOYSA-N 0.000 claims 1
- YQPBVMJEHQWBSQ-UHFFFAOYSA-N 1-[[3-(thiophene-3-carbonylamino)phenyl]methyl]piperidine-4-carboxylic acid Chemical group S1C=C(C=C1)C(=O)NC=1C=C(CN2CCC(CC2)C(=O)O)C=CC1 YQPBVMJEHQWBSQ-UHFFFAOYSA-N 0.000 claims 1
- SRJNJPQHDSHRTL-UHFFFAOYSA-N 1-[[3-[(4-chlorobenzoyl)amino]phenyl]methyl]-N-(pyridin-2-ylmethyl)piperidine-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(=O)NC1=CC=CC(CN2CCC(CC2)C(=O)NCC=2N=CC=CC=2)=C1 SRJNJPQHDSHRTL-UHFFFAOYSA-N 0.000 claims 1
- ZBECGCBSMMAODF-UHFFFAOYSA-N 1-[[3-[(7-chloro-2,3-dihydro-1-benzofuran-4-carbonyl)amino]phenyl]methyl]-N-cyclohexylpiperidine-4-carboxamide Chemical compound C1=2CCOC=2C(Cl)=CC=C1C(=O)NC(C=1)=CC=CC=1CN(CC1)CCC1C(=O)NC1CCCCC1 ZBECGCBSMMAODF-UHFFFAOYSA-N 0.000 claims 1
- ASSGWVBTWBZKGL-UHFFFAOYSA-N 1-[[3-[[2-(2-chlorophenyl)acetyl]amino]phenyl]methyl]-N-cyclohexylpiperidine-4-carboxamide Chemical compound ClC1=CC=CC=C1CC(=O)NC1=CC=CC(CN2CCC(CC2)C(=O)NC2CCCCC2)=C1 ASSGWVBTWBZKGL-UHFFFAOYSA-N 0.000 claims 1
- GDBPTOPLCQTNPP-UHFFFAOYSA-N 1-[[3-[[2-(4-chlorophenyl)acetyl]amino]phenyl]methyl]-N-cyclohexylpiperidine-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1CC(=O)NC1=CC=CC(CN2CCC(CC2)C(=O)NC2CCCCC2)=C1 GDBPTOPLCQTNPP-UHFFFAOYSA-N 0.000 claims 1
- DKLQJNUJPSHYQG-UHFFFAOYSA-N 2-cyclohexylacetamide Chemical compound NC(=O)CC1CCCCC1 DKLQJNUJPSHYQG-UHFFFAOYSA-N 0.000 claims 1
- GPWHFPWZAPOYNO-UHFFFAOYSA-N 3,3-dimethylbutan-1-amine Chemical compound CC(C)(C)CCN GPWHFPWZAPOYNO-UHFFFAOYSA-N 0.000 claims 1
- CGOIBYYWOVRGGV-UHFFFAOYSA-N 3,5-difluorobenzamide Chemical compound NC(=O)C1=CC(F)=CC(F)=C1 CGOIBYYWOVRGGV-UHFFFAOYSA-N 0.000 claims 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- MLDNJWBAASRVGP-UHFFFAOYSA-N 5-methyl-N-[3-[[4-(2-methylpyrrolidine-1-carbonyl)piperidin-1-yl]methyl]phenyl]pyridine-3-carboxamide Chemical compound CC1CCCN1C(=O)C1CCN(CC=2C=C(NC(=O)C=3C=C(C)C=NC=3)C=CC=2)CC1 MLDNJWBAASRVGP-UHFFFAOYSA-N 0.000 claims 1
- AIHLALPAPQQMMF-UHFFFAOYSA-N N-[3-[[4-(cyclohexylcarbamoyl)piperidin-1-yl]methyl]phenyl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound O1C(C)=CC(C(=O)NC=2C=C(CN3CCC(CC3)C(=O)NC3CCCCC3)C=CC=2)=N1 AIHLALPAPQQMMF-UHFFFAOYSA-N 0.000 claims 1
- PZPPUJKMJLOJCE-UHFFFAOYSA-N N-cyclohexyl-1-[[3-(cyclopentanecarbonylamino)phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CCCC1C(=O)NC(C=1)=CC=CC=1CN(CC1)CCC1C(=O)NC1CCCCC1 PZPPUJKMJLOJCE-UHFFFAOYSA-N 0.000 claims 1
- RCWLVJLIXGGKAS-UHFFFAOYSA-N N-cyclohexyl-1-[[3-[(2-cyclohexylacetyl)amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C=1C=CC(CN2CCC(CC2)C(=O)NC2CCCCC2)=CC=1NC(=O)CC1CCCCC1 RCWLVJLIXGGKAS-UHFFFAOYSA-N 0.000 claims 1
- ZTZLWKZIIVDBSE-UHFFFAOYSA-N N-tert-butyl-1-[[3-[(1-phenylcyclopropanecarbonyl)amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)C2(CC2)C=2C=CC=CC=2)=C1 ZTZLWKZIIVDBSE-UHFFFAOYSA-N 0.000 claims 1
- SJJVGUCLCIXLMY-UHFFFAOYSA-N N-tert-butyl-1-[[3-[[2-(2,4-dichloro-5-fluorophenyl)acetyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)CC=2C(=CC(Cl)=C(F)C=2)Cl)=C1 SJJVGUCLCIXLMY-UHFFFAOYSA-N 0.000 claims 1
- KOCYPVCEIWUFJQ-UHFFFAOYSA-N N-tert-butyl-1-[[3-[[2-(2,4-dichlorophenyl)acetyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)CC=2C(=CC(Cl)=CC=2)Cl)=C1 KOCYPVCEIWUFJQ-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical group 0.000 claims 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- FMICLUUBYMZQIO-UHFFFAOYSA-N butan-1-amine formamide Chemical compound C(CCC)N.C(=O)N FMICLUUBYMZQIO-UHFFFAOYSA-N 0.000 claims 1
- 239000001273 butane Substances 0.000 claims 1
- YFWWKUHSWXHMPO-UHFFFAOYSA-N cyclopentanamine formamide Chemical compound C(=O)N.NC1CCCC1 YFWWKUHSWXHMPO-UHFFFAOYSA-N 0.000 claims 1
- UBLYEVLMRSPMOG-UHFFFAOYSA-N cyclopentylmethanamine Chemical compound NCC1CCCC1 UBLYEVLMRSPMOG-UHFFFAOYSA-N 0.000 claims 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 208000035474 group of disease Diseases 0.000 claims 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Natural products OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 claims 1
- ZMGCELMSGYDGBK-UHFFFAOYSA-N n-cyclohexyl-1-[[3-(1h-pyrrole-2-carbonylamino)phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CN(CC=2C=C(NC(=O)C=3NC=CC=3)C=CC=2)CCC1C(=O)NC1CCCCC1 ZMGCELMSGYDGBK-UHFFFAOYSA-N 0.000 claims 1
- MPIAOHRYJVHGPW-UHFFFAOYSA-N n-cyclohexyl-1-[[3-[(5-methylthiophene-2-carbonyl)amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound S1C(C)=CC=C1C(=O)NC1=CC=CC(CN2CCC(CC2)C(=O)NC2CCCCC2)=C1 MPIAOHRYJVHGPW-UHFFFAOYSA-N 0.000 claims 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims 1
- QRBTUJUIFNHOIZ-UHFFFAOYSA-N n-tert-butyl-1-[[3-(2-phenylpropanoylamino)phenyl]methyl]piperidine-4-carboxamide Chemical compound C=1C=CC=CC=1C(C)C(=O)NC(C=1)=CC=CC=1CN1CCC(C(=O)NC(C)(C)C)CC1 QRBTUJUIFNHOIZ-UHFFFAOYSA-N 0.000 claims 1
- ZLBXRVQBCDYCII-UHFFFAOYSA-N n-tert-butyl-1-[[3-[[1-(2,4-dichlorophenyl)cyclopropanecarbonyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)C2(CC2)C=2C(=CC(Cl)=CC=2)Cl)=C1 ZLBXRVQBCDYCII-UHFFFAOYSA-N 0.000 claims 1
- YIKXIRZZHOYOGP-UHFFFAOYSA-N n-tert-butyl-1-[[3-[[2-(2,5-dimethyl-1,3-thiazol-4-yl)acetyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound S1C(C)=NC(CC(=O)NC=2C=C(CN3CCC(CC3)C(=O)NC(C)(C)C)C=CC=2)=C1C YIKXIRZZHOYOGP-UHFFFAOYSA-N 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 abstract description 48
- 101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 abstract description 48
- 125000005002 aryl methyl group Chemical group 0.000 abstract description 3
- 229940075993 receptor modulator Drugs 0.000 abstract 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 124
- 238000006243 chemical reaction Methods 0.000 description 76
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 74
- 239000000203 mixture Substances 0.000 description 65
- 239000000243 solution Substances 0.000 description 59
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 40
- 238000000034 method Methods 0.000 description 34
- 239000002904 solvent Substances 0.000 description 31
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 239000012074 organic phase Substances 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 230000009467 reduction Effects 0.000 description 21
- 238000006722 reduction reaction Methods 0.000 description 21
- 235000019439 ethyl acetate Nutrition 0.000 description 20
- 239000002253 acid Substances 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 19
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 18
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 18
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 18
- 235000011150 stannous chloride Nutrition 0.000 description 18
- 239000001119 stannous chloride Substances 0.000 description 18
- 239000000843 powder Substances 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 150000001412 amines Chemical class 0.000 description 16
- 201000006417 multiple sclerosis Diseases 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000002585 base Substances 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 239000008346 aqueous phase Substances 0.000 description 14
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- NFEWOIKMJZYUTQ-UHFFFAOYSA-N n-cyclohexylpiperidine-4-carboxamide;hydrochloride Chemical compound Cl.C1CNCCC1C(=O)NC1CCCCC1 NFEWOIKMJZYUTQ-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- RVLXBOPJKYOSKH-UHFFFAOYSA-N n-tert-butylpiperidine-4-carboxamide Chemical compound CC(C)(C)NC(=O)C1CCNCC1 RVLXBOPJKYOSKH-UHFFFAOYSA-N 0.000 description 11
- 238000006268 reductive amination reaction Methods 0.000 description 11
- JQZAEUFPPSRDOP-UHFFFAOYSA-N 1-chloro-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1 JQZAEUFPPSRDOP-UHFFFAOYSA-N 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 206010039073 rheumatoid arthritis Diseases 0.000 description 10
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 9
- 150000001408 amides Chemical class 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- 238000002953 preparative HPLC Methods 0.000 description 9
- 125000004076 pyridyl group Chemical group 0.000 description 9
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 7
- 206010025323 Lymphomas Diseases 0.000 description 7
- QOSSAOTZNIDXMA-UHFFFAOYSA-N N,N′-Dicyclohexylcarbodiimide Substances C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 7
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- RUJPPJYDHHAEEK-UHFFFAOYSA-N ethyl piperidine-4-carboxylate Chemical compound CCOC(=O)C1CCNCC1 RUJPPJYDHHAEEK-UHFFFAOYSA-N 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000007821 HATU Substances 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000007488 abnormal function Effects 0.000 description 6
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 6
- 239000012346 acetyl chloride Substances 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 6
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- DZZYVVUYEDSKBU-UHFFFAOYSA-N 3-(chloromethyl)-5-methylpyridine Chemical compound CC1=CN=CC(CCl)=C1 DZZYVVUYEDSKBU-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 206010005003 Bladder cancer Diseases 0.000 description 5
- 206010008342 Cervix carcinoma Diseases 0.000 description 5
- 102000009410 Chemokine receptor Human genes 0.000 description 5
- 108050000299 Chemokine receptor Proteins 0.000 description 5
- 208000032612 Glial tumor Diseases 0.000 description 5
- 206010018338 Glioma Diseases 0.000 description 5
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 5
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 239000012317 TBTU Substances 0.000 description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 5
- GPDHNZNLPKYHCN-DZOOLQPHSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-morpholin-4-ylmethylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CCOC(=O)C(\C#N)=N/OC(=[N+](C)C)N1CCOCC1 GPDHNZNLPKYHCN-DZOOLQPHSA-N 0.000 description 5
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 5
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 5
- 201000010881 cervical cancer Diseases 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 5
- 125000001041 indolyl group Chemical group 0.000 description 5
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 5
- 125000000842 isoxazolyl group Chemical group 0.000 description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 201000002528 pancreatic cancer Diseases 0.000 description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 description 5
- 125000003226 pyrazolyl group Chemical group 0.000 description 5
- 125000002098 pyridazinyl group Chemical group 0.000 description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 description 5
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 5
- 125000000168 pyrrolyl group Chemical group 0.000 description 5
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 5
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 125000000335 thiazolyl group Chemical group 0.000 description 5
- 125000001544 thienyl group Chemical group 0.000 description 5
- 201000005112 urinary bladder cancer Diseases 0.000 description 5
- NFFASAJHNHQAMQ-UHFFFAOYSA-N 1-[(3-aminophenyl)methyl]-n-cyclohexylpiperidine-4-carboxamide Chemical compound NC1=CC=CC(CN2CCC(CC2)C(=O)NC2CCCCC2)=C1 NFFASAJHNHQAMQ-UHFFFAOYSA-N 0.000 description 4
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 208000015943 Coeliac disease Diseases 0.000 description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 4
- 208000006168 Ewing Sarcoma Diseases 0.000 description 4
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 4
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 4
- 208000005615 Interstitial Cystitis Diseases 0.000 description 4
- 208000007766 Kaposi sarcoma Diseases 0.000 description 4
- 208000005777 Lupus Nephritis Diseases 0.000 description 4
- 201000003791 MALT lymphoma Diseases 0.000 description 4
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 150000001241 acetals Chemical class 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 229910052805 deuterium Inorganic materials 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 201000002491 encephalomyelitis Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 201000010175 gallbladder cancer Diseases 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 206010027191 meningioma Diseases 0.000 description 4
- SUECUXVKMPTLRH-UHFFFAOYSA-N n-cyclohexylpiperidine-4-carboxamide Chemical compound C1CNCCC1C(=O)NC1CCCCC1 SUECUXVKMPTLRH-UHFFFAOYSA-N 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 201000008968 osteosarcoma Diseases 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 208000002815 pulmonary hypertension Diseases 0.000 description 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- NBVPTQRFNRBXGB-UHFFFAOYSA-N (5-amino-2-fluorophenyl)methanol Chemical compound NC1=CC=C(F)C(CO)=C1 NBVPTQRFNRBXGB-UHFFFAOYSA-N 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- CGXJUBDTCAAXAY-UHFFFAOYSA-N 1-(3-aminophenyl)propan-1-one Chemical compound CCC(=O)C1=CC=CC(N)=C1 CGXJUBDTCAAXAY-UHFFFAOYSA-N 0.000 description 3
- FUYHFQRMFJNQNY-UHFFFAOYSA-N 1-[(3-aminophenyl)methyl]-n-tert-butylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(N)=C1 FUYHFQRMFJNQNY-UHFFFAOYSA-N 0.000 description 3
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- JGILMNHDPYZDPZ-UHFFFAOYSA-N 3-chloro-6-methylpyridazine-4-carboxylic acid Chemical compound CC1=CC(C(O)=O)=C(Cl)N=N1 JGILMNHDPYZDPZ-UHFFFAOYSA-N 0.000 description 3
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 3
- IFPKRANDHTYRSN-UHFFFAOYSA-N 4-chloro-n-(3-formylphenyl)benzamide Chemical compound C1=CC(Cl)=CC=C1C(=O)NC1=CC=CC(C=O)=C1 IFPKRANDHTYRSN-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- DNJZRTAJMOEIAQ-UHFFFAOYSA-N CCC(=O)C1=CC(=CC=C1)NC(=O)O Chemical compound CCC(=O)C1=CC(=CC=C1)NC(=O)O DNJZRTAJMOEIAQ-UHFFFAOYSA-N 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 208000009525 Myocarditis Diseases 0.000 description 3
- 208000033626 Renal failure acute Diseases 0.000 description 3
- 206010046851 Uveitis Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 201000011040 acute kidney failure Diseases 0.000 description 3
- 208000012998 acute renal failure Diseases 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 3
- 238000000105 evaporative light scattering detection Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000004129 indan-1-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])([H])C2([H])* 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- ZXWVWQFBCSZTHB-UHFFFAOYSA-N n-cyclopentylpiperidine-4-carboxamide Chemical compound C1CNCCC1C(=O)NC1CCCC1 ZXWVWQFBCSZTHB-UHFFFAOYSA-N 0.000 description 3
- OPPSCBXDBJJMGS-UHFFFAOYSA-N n-tert-butylpiperidine-4-carboxamide;hydrochloride Chemical compound Cl.CC(C)(C)NC(=O)C1CCNCC1 OPPSCBXDBJJMGS-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 201000003774 sarcomatosis Diseases 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- PBIMIGNDTBRRPI-UHFFFAOYSA-N trifluoro borate Chemical compound FOB(OF)OF PBIMIGNDTBRRPI-UHFFFAOYSA-N 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- MOQXFCQZXXBZRO-UHFFFAOYSA-N 1-[(2-amino-1,3-thiazol-4-yl)methyl]-N-cyclopentylpiperidine-4-carboxamide Chemical compound S1C(N)=NC(CN2CCC(CC2)C(=O)NC2CCCC2)=C1 MOQXFCQZXXBZRO-UHFFFAOYSA-N 0.000 description 2
- XNFZFQZJANARGI-UHFFFAOYSA-N 1-[(3-amino-5-methylphenyl)methyl]-N-tert-butylpiperidine-4-carboxamide Chemical compound CC1=CC(N)=CC(CN2CCC(CC2)C(=O)NC(C)(C)C)=C1 XNFZFQZJANARGI-UHFFFAOYSA-N 0.000 description 2
- VLQMRTKOYOGVMG-UHFFFAOYSA-N 1-[(3-aminophenyl)methyl]-N-cyclopropylpiperidine-4-carboxamide Chemical compound NC1=CC=CC(CN2CCC(CC2)C(=O)NC2CC2)=C1 VLQMRTKOYOGVMG-UHFFFAOYSA-N 0.000 description 2
- OOOCWFGJAHANIV-UHFFFAOYSA-N 1-[1-(3-aminophenyl)ethyl]-N-cyclohexylpiperidine-4-carboxamide Chemical compound C=1C=CC(N)=CC=1C(C)N(CC1)CCC1C(=O)NC1CCCCC1 OOOCWFGJAHANIV-UHFFFAOYSA-N 0.000 description 2
- LTVBBAUSGXRYAG-UHFFFAOYSA-N 1-[1-(3-aminophenyl)propyl]-N-cyclohexylpiperidine-4-carboxamide Chemical compound C=1C=CC(N)=CC=1C(CC)N(CC1)CCC1C(=O)NC1CCCCC1 LTVBBAUSGXRYAG-UHFFFAOYSA-N 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- PHODFIDDEBEGCS-UHFFFAOYSA-N 2,2-dimethylpyrrolidine Chemical compound CC1(C)CCCN1 PHODFIDDEBEGCS-UHFFFAOYSA-N 0.000 description 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 2
- ZEBFPAXSQXIPNF-UHFFFAOYSA-N 2,5-dimethylpyrrolidine Chemical compound CC1CCC(C)N1 ZEBFPAXSQXIPNF-UHFFFAOYSA-N 0.000 description 2
- JWAQENUKTAOJST-UHFFFAOYSA-N 2-(chloromethyl)pyrimidin-4-amine Chemical compound NC1=CC=NC(CCl)=N1 JWAQENUKTAOJST-UHFFFAOYSA-N 0.000 description 2
- RGHPCLZJAFCTIK-UHFFFAOYSA-N 2-methylpyrrolidine Chemical compound CC1CCCN1 RGHPCLZJAFCTIK-UHFFFAOYSA-N 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- KVTUSMPNLUCCQO-UHFFFAOYSA-N 3,3-difluoropyrrolidine Chemical compound FC1(F)CCNC1 KVTUSMPNLUCCQO-UHFFFAOYSA-N 0.000 description 2
- XBQNZPDIRJPFAI-UHFFFAOYSA-N 3,3-dimethylpyrrolidine Chemical compound CC1(C)CCNC1 XBQNZPDIRJPFAI-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 2
- CDDGNGVFPQRJJM-UHFFFAOYSA-N 3-fluoropyrrolidine Chemical compound FC1CCNC1 CDDGNGVFPQRJJM-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- MJOUJKDTBGXKIU-UHFFFAOYSA-N 4,4-difluoropiperidine Chemical compound FC1(F)CCNCC1 MJOUJKDTBGXKIU-UHFFFAOYSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- AOBOFIJRMUVYOK-UHFFFAOYSA-N 5-methyl-2-phenylpyridine-3-carboxamide Chemical compound C1(=CC=CC=C1)C1=C(C(=O)N)C=C(C=N1)C AOBOFIJRMUVYOK-UHFFFAOYSA-N 0.000 description 2
- DJDHHXDFKSLEQY-UHFFFAOYSA-N 5-methylpyridine-3-carboxylic acid Chemical compound CC1=CN=CC(C(O)=O)=C1 DJDHHXDFKSLEQY-UHFFFAOYSA-N 0.000 description 2
- UMVDJTLECBAYCO-UHFFFAOYSA-N 6-methylpyridazine-4-carboxylic acid Chemical compound CC1=CC(C(O)=O)=CN=N1 UMVDJTLECBAYCO-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- 206010009137 Chronic sinusitis Diseases 0.000 description 2
- CNSIJDGYQVCYEJ-UHFFFAOYSA-N ClC1=CC=C(C(=O)NC2=CC(=CC=C2)C2OC=CO2)C=C1 Chemical compound ClC1=CC=C(C(=O)NC2=CC(=CC=C2)C2OC=CO2)C=C1 CNSIJDGYQVCYEJ-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 101000666856 Homo sapiens Vasoactive intestinal polypeptide receptor 1 Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- QMELSORYAUEFJB-UHFFFAOYSA-N N-cyclohexyl-1-[1-(3-nitrophenyl)ethyl]piperidine-4-carboxamide Chemical compound C=1C=CC([N+]([O-])=O)=CC=1C(C)N(CC1)CCC1C(=O)NC1CCCCC1 QMELSORYAUEFJB-UHFFFAOYSA-N 0.000 description 2
- SBGGLVXKYHEJEG-UHFFFAOYSA-N N-cyclohexyl-1-[1-(3-nitrophenyl)propyl]piperidine-4-carboxamide Chemical compound C=1C=CC([N+]([O-])=O)=CC=1C(CC)N(CC1)CCC1C(=O)NC1CCCCC1 SBGGLVXKYHEJEG-UHFFFAOYSA-N 0.000 description 2
- YIXNLZVMVAKDNC-UHFFFAOYSA-N N-tert-butyl-1-[(3-methyl-5-nitrophenyl)methyl]piperidine-4-carboxamide Chemical compound [O-][N+](=O)C1=CC(C)=CC(CN2CCC(CC2)C(=O)NC(C)(C)C)=C1 YIXNLZVMVAKDNC-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- XEVFEKVZWCHGBN-UHFFFAOYSA-N O1C(OC=C1)C=1C=C(C=CC1)NC(C1=CN=CC(=C1)C)=O Chemical compound O1C(OC=C1)C=1C=C(C=CC1)NC(C1=CN=CC(=C1)C)=O XEVFEKVZWCHGBN-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 102000000804 Pregnane X Receptor Human genes 0.000 description 2
- 108010001511 Pregnane X Receptor Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000011191 Pulmonary vascular disease Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 206010039705 Scleritis Diseases 0.000 description 2
- 108010079723 Shiga Toxin Proteins 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000024248 Vascular System injury Diseases 0.000 description 2
- 208000012339 Vascular injury Diseases 0.000 description 2
- 241000710886 West Nile virus Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 125000006449 cycloalkyl cyclopropyl group Chemical group 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 2
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004552 isoquinolin-4-yl group Chemical group C1=NC=C(C2=CC=CC=C12)* 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- VVWWZOKQKXPVIV-UHFFFAOYSA-N methyl pyrrolidine-3-carboxylate Chemical compound COC(=O)C1CCNC1 VVWWZOKQKXPVIV-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- KXRVFLWWMYHCJH-UHFFFAOYSA-N n-(6-chloropyrimidin-4-yl)-6-(trifluoromethyl)pyridine-2-carboxamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)NC=2N=CN=C(Cl)C=2)=N1 KXRVFLWWMYHCJH-UHFFFAOYSA-N 0.000 description 2
- NXMDNPADUCLDMX-UHFFFAOYSA-N n-cyclopentylpiperidine-4-carboxamide;hydrochloride Chemical compound Cl.C1CNCCC1C(=O)NC1CCCC1 NXMDNPADUCLDMX-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 125000006502 nitrobenzyl group Chemical group 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 2
- 201000011461 pre-eclampsia Diseases 0.000 description 2
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 2
- CBKWAXKMZUULLO-UHFFFAOYSA-N (2-chloro-4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1Cl CBKWAXKMZUULLO-UHFFFAOYSA-N 0.000 description 1
- XEULVOWBZXADRO-UHFFFAOYSA-N (3-formylphenyl)carbamic acid Chemical compound OC(=O)NC1=CC=CC(C=O)=C1 XEULVOWBZXADRO-UHFFFAOYSA-N 0.000 description 1
- AYPGGLUMIIXJFN-UHFFFAOYSA-N (4-propanoyl-1,3-thiazol-2-yl)carbamic acid Chemical compound CCC(=O)C1=CSC(NC(O)=O)=N1 AYPGGLUMIIXJFN-UHFFFAOYSA-N 0.000 description 1
- IVSZLXZYQVIEFR-UHFFFAOYSA-N 1,3-Dimethylbenzene Natural products CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 1
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
- ARKIFHPFTHVKDT-UHFFFAOYSA-N 1-(3-nitrophenyl)ethanone Chemical compound CC(=O)C1=CC=CC([N+]([O-])=O)=C1 ARKIFHPFTHVKDT-UHFFFAOYSA-N 0.000 description 1
- LSEJDXFJBNGGBI-UHFFFAOYSA-N 1-(3-nitrophenyl)propan-1-ol Chemical compound CCC(O)C1=CC=CC([N+]([O-])=O)=C1 LSEJDXFJBNGGBI-UHFFFAOYSA-N 0.000 description 1
- MAIJBMCPDXRFNI-UHFFFAOYSA-N 1-[(2-bromo-5-nitrophenyl)methyl]-N-tert-butylpiperidine-4-carboxamide Chemical compound C(C)(C)(C)NC(=O)C1CCN(CC1)CC1=C(C=CC(=C1)[N+](=O)[O-])Br MAIJBMCPDXRFNI-UHFFFAOYSA-N 0.000 description 1
- JBASZVXHSJZRAQ-UHFFFAOYSA-N 1-[(2-bromopyridin-4-yl)methyl]-n-cyclohexylpiperidine-4-carboxamide Chemical compound C1=NC(Br)=CC(CN2CCC(CC2)C(=O)NC2CCCCC2)=C1 JBASZVXHSJZRAQ-UHFFFAOYSA-N 0.000 description 1
- SYSQCAFDMYRQFK-UHFFFAOYSA-N 1-[(2-chloropyridin-4-yl)methyl]-n-cyclohexylpiperidine-4-carboxamide Chemical compound C1=NC(Cl)=CC(CN2CCC(CC2)C(=O)NC2CCCCC2)=C1 SYSQCAFDMYRQFK-UHFFFAOYSA-N 0.000 description 1
- VTSMVPALSJYQLX-UHFFFAOYSA-N 1-[(3-amino-2-chlorophenyl)methyl]-n-cyclohexylpiperidine-4-carboxamide Chemical compound NC1=CC=CC(CN2CCC(CC2)C(=O)NC2CCCCC2)=C1Cl VTSMVPALSJYQLX-UHFFFAOYSA-N 0.000 description 1
- QVZUIHQJDDGRLS-UHFFFAOYSA-N 1-[(3-amino-2-methoxyphenyl)methyl]-n-tert-butylpiperidine-4-carboxamide Chemical compound COC1=C(N)C=CC=C1CN1CCC(C(=O)NC(C)(C)C)CC1 QVZUIHQJDDGRLS-UHFFFAOYSA-N 0.000 description 1
- YFMDFGZMTSUYNH-UHFFFAOYSA-N 1-[(3-amino-2-methylphenyl)methyl]-n-tert-butylpiperidine-4-carboxamide Chemical compound CC1=C(N)C=CC=C1CN1CCC(C(=O)NC(C)(C)C)CC1 YFMDFGZMTSUYNH-UHFFFAOYSA-N 0.000 description 1
- GREPNVBKKIKTID-UHFFFAOYSA-N 1-[(3-amino-4-chlorophenyl)methyl]-n-cyclohexylpiperidine-4-carboxamide Chemical compound C1=C(Cl)C(N)=CC(CN2CCC(CC2)C(=O)NC2CCCCC2)=C1 GREPNVBKKIKTID-UHFFFAOYSA-N 0.000 description 1
- OJHZCZLLUBZANO-UHFFFAOYSA-N 1-[(3-amino-4-ethylphenyl)methyl]-N-tert-butylpiperidine-4-carboxamide Chemical compound CCc1ccc(CN2CCC(CC2)C(=O)NC(C)(C)C)cc1N OJHZCZLLUBZANO-UHFFFAOYSA-N 0.000 description 1
- UNEGLRQALSCZKN-UHFFFAOYSA-N 1-[(3-amino-4-methoxyphenyl)methyl]-n-tert-butylpiperidine-4-carboxamide Chemical compound C1=C(N)C(OC)=CC=C1CN1CCC(C(=O)NC(C)(C)C)CC1 UNEGLRQALSCZKN-UHFFFAOYSA-N 0.000 description 1
- ZFNIEESCIUIJAS-UHFFFAOYSA-N 1-[(3-amino-4-methylphenyl)methyl]-N-tert-butylpiperidine-4-carboxamide Chemical compound C1=C(N)C(C)=CC=C1CN1CCC(C(=O)NC(C)(C)C)CC1 ZFNIEESCIUIJAS-UHFFFAOYSA-N 0.000 description 1
- FSPZMIAXOFOHKN-UHFFFAOYSA-N 1-[(3-amino-5-bromophenyl)methyl]-n-tert-butylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC(N)=CC(Br)=C1 FSPZMIAXOFOHKN-UHFFFAOYSA-N 0.000 description 1
- JZOPYXDVWODKLA-UHFFFAOYSA-N 1-[(3-amino-5-methoxyphenyl)methyl]-n-tert-butylpiperidine-4-carboxamide Chemical compound COC1=CC(N)=CC(CN2CCC(CC2)C(=O)NC(C)(C)C)=C1 JZOPYXDVWODKLA-UHFFFAOYSA-N 0.000 description 1
- NIOPLTJRTDQUMS-UHFFFAOYSA-N 1-[(3-aminophenyl)methyl]-N-(2-methylbutan-2-yl)piperidine-4-carboxamide Chemical compound CC(CC)(C)NC(=O)C1CCN(CC1)CC1=CC(=CC=C1)N NIOPLTJRTDQUMS-UHFFFAOYSA-N 0.000 description 1
- KRDAZCQNLFQBKF-UHFFFAOYSA-N 1-[(3-aminophenyl)methyl]-N-cyclopentylpiperidine-4-carboxamide Chemical compound NC1=CC=CC(CN2CCC(CC2)C(=O)NC2CCCC2)=C1 KRDAZCQNLFQBKF-UHFFFAOYSA-N 0.000 description 1
- RNSFBNWUMHNNOX-UHFFFAOYSA-N 1-[(3-aminophenyl)methyl]-n-methyl-n-(2-methylpropyl)piperidine-4-carboxamide Chemical compound C1CC(C(=O)N(C)CC(C)C)CCN1CC1=CC=CC(N)=C1 RNSFBNWUMHNNOX-UHFFFAOYSA-N 0.000 description 1
- KWDOQYRJGUPGBM-UHFFFAOYSA-N 1-[(3-aminophenyl)methyl]piperidine-4-carboxylic acid Chemical class NC1=CC=CC(CN2CCC(CC2)C(O)=O)=C1 KWDOQYRJGUPGBM-UHFFFAOYSA-N 0.000 description 1
- RBSFHFQTKHIVPJ-UHFFFAOYSA-N 1-[(3-bromo-5-nitrophenyl)methyl]-N-tert-butylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC(Br)=CC([N+]([O-])=O)=C1 RBSFHFQTKHIVPJ-UHFFFAOYSA-N 0.000 description 1
- WSJBABIQUJZITR-UHFFFAOYSA-N 1-[(4-aminopyrimidin-2-yl)methyl]-n-cyclohexylpiperidine-4-carboxamide Chemical compound NC1=CC=NC(CN2CCC(CC2)C(=O)NC2CCCCC2)=N1 WSJBABIQUJZITR-UHFFFAOYSA-N 0.000 description 1
- SIQKZPIJAGAZIF-UHFFFAOYSA-N 1-[(4-aminopyrimidin-2-yl)methyl]-n-tert-butylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=NC=CC(N)=N1 SIQKZPIJAGAZIF-UHFFFAOYSA-N 0.000 description 1
- JKNVLAAUIUBMET-UHFFFAOYSA-N 1-[(4-bromothiophen-2-yl)methyl]-n-tert-butylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC(Br)=CS1 JKNVLAAUIUBMET-UHFFFAOYSA-N 0.000 description 1
- WYGRLIUHUPKVAB-UHFFFAOYSA-N 1-[(4-chloropyridin-2-yl)methyl]-n-cyclohexylpiperidine-4-carboxamide Chemical compound ClC1=CC=NC(CN2CCC(CC2)C(=O)NC2CCCCC2)=C1 WYGRLIUHUPKVAB-UHFFFAOYSA-N 0.000 description 1
- VAZTUKKRUFELFU-UHFFFAOYSA-N 1-[(5-amino-2-chlorophenyl)methyl]-N-cyclopentylpiperidine-4-carboxamide Chemical compound NC1=CC=C(Cl)C(CN2CCC(CC2)C(=O)NC2CCCC2)=C1 VAZTUKKRUFELFU-UHFFFAOYSA-N 0.000 description 1
- ZRYOJLQMTNIZQV-UHFFFAOYSA-N 1-[(5-amino-2-ethylphenyl)methyl]-N-tert-butylpiperidine-4-carboxamide Chemical compound CCc1ccc(N)cc1CN1CCC(CC1)C(=O)NC(C)(C)C ZRYOJLQMTNIZQV-UHFFFAOYSA-N 0.000 description 1
- YSKVDILCWMPLQU-UHFFFAOYSA-N 1-[(5-amino-2-methoxyphenyl)methyl]-n-tert-butylpiperidine-4-carboxamide Chemical compound COC1=CC=C(N)C=C1CN1CCC(C(=O)NC(C)(C)C)CC1 YSKVDILCWMPLQU-UHFFFAOYSA-N 0.000 description 1
- JSKNQKMZHOBIND-UHFFFAOYSA-N 1-[(5-amino-2-methylphenyl)methyl]-n-tert-butylpiperidine-4-carboxamide Chemical compound CC1=CC=C(N)C=C1CN1CCC(C(=O)NC(C)(C)C)CC1 JSKNQKMZHOBIND-UHFFFAOYSA-N 0.000 description 1
- AFKFUYROKBOVPX-UHFFFAOYSA-N 1-[(5-bromopyridin-3-yl)methyl]-n-cyclohexylpiperidine-4-carboxamide Chemical compound BrC1=CN=CC(CN2CCC(CC2)C(=O)NC2CCCCC2)=C1 AFKFUYROKBOVPX-UHFFFAOYSA-N 0.000 description 1
- XROMYCITAFGWSO-UHFFFAOYSA-N 1-[(5-bromothiophen-3-yl)methyl]-n-tert-butylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CSC(Br)=C1 XROMYCITAFGWSO-UHFFFAOYSA-N 0.000 description 1
- NQCVICLWZRAVLG-UHFFFAOYSA-N 1-[(6-bromopyridin-2-yl)methyl]-n-cyclohexylpiperidine-4-carboxamide Chemical compound BrC1=CC=CC(CN2CCC(CC2)C(=O)NC2CCCCC2)=N1 NQCVICLWZRAVLG-UHFFFAOYSA-N 0.000 description 1
- MKLSOJYDZOGGNC-UHFFFAOYSA-N 1-[[3-(1H-pyrrole-2-carbonylamino)phenyl]methyl]piperidine-4-carboxylic acid Chemical group N1C(=CC=C1)C(=O)NC=1C=C(CN2CCC(CC2)C(=O)O)C=CC1 MKLSOJYDZOGGNC-UHFFFAOYSA-N 0.000 description 1
- XZHAIDMIRVVWCN-UHFFFAOYSA-N 1-[[3-(cyclobutanecarbonylamino)phenyl]methyl]-N-cyclohexylpiperidine-4-carboxamide Chemical compound C1CCC1C(=O)NC(C=1)=CC=CC=1CN(CC1)CCC1C(=O)NC1CCCCC1 XZHAIDMIRVVWCN-UHFFFAOYSA-N 0.000 description 1
- MXYGHWXYFPGCGQ-UHFFFAOYSA-N 1-[[3-(thiophene-2-carbonylamino)phenyl]methyl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1CC1=CC=CC(NC(=O)C=2SC=CC=2)=C1 MXYGHWXYFPGCGQ-UHFFFAOYSA-N 0.000 description 1
- HWTBWSBJGBBPPX-UHFFFAOYSA-N 1-[[3-[(5-methylpyridine-3-carbonyl)amino]phenyl]methyl]piperidine-4-carboxylic acid Chemical compound CC1=CN=CC(C(=O)NC=2C=C(CN3CCC(CC3)C(O)=O)C=CC=2)=C1 HWTBWSBJGBBPPX-UHFFFAOYSA-N 0.000 description 1
- BFUIKNVWVVLACT-UHFFFAOYSA-N 1-[[3-[(5-methylpyridine-3-carbonyl)amino]phenyl]methyl]pyrrolidine-3-carboxylic acid Chemical compound CC1=CN=CC(C(=O)NC=2C=C(CN3CC(CC3)C(O)=O)C=CC=2)=C1 BFUIKNVWVVLACT-UHFFFAOYSA-N 0.000 description 1
- WDHSAMOXTWJFFY-UHFFFAOYSA-N 1-[[3-[[2-(2,3-dihydro-1H-inden-2-yl)acetyl]amino]phenyl]methyl]piperidine-4-carboxylic acid Chemical compound OC(=O)C1CCN(Cc2cccc(NC(=O)CC3Cc4ccccc4C3)c2)CC1 WDHSAMOXTWJFFY-UHFFFAOYSA-N 0.000 description 1
- KVNLTVNXOYLHJX-UHFFFAOYSA-N 1-[[3-[[6-(trifluoromethyl)pyridine-2-carbonyl]amino]phenyl]methyl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1CC1=CC=CC(NC(=O)C=2N=C(C=CC=2)C(F)(F)F)=C1 KVNLTVNXOYLHJX-UHFFFAOYSA-N 0.000 description 1
- MRFUETISGNPREN-UHFFFAOYSA-N 1-[[3-[[6-(trifluoromethyl)pyridine-2-carbonyl]amino]phenyl]methyl]pyrrolidine-3-carboxylic acid Chemical compound FC(C1=CC=CC(=N1)C(=O)NC=1C=C(CN2CC(CC2)C(=O)O)C=CC=1)(F)F MRFUETISGNPREN-UHFFFAOYSA-N 0.000 description 1
- VZHJIJZEOCBKRA-UHFFFAOYSA-N 1-chloro-3-fluorobenzene Chemical group FC1=CC=CC(Cl)=C1 VZHJIJZEOCBKRA-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- DXMRZBGFYBCTLR-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine-2-carboxylic acid Chemical compound C1=CN=C2NC(C(=O)O)=CC2=C1 DXMRZBGFYBCTLR-UHFFFAOYSA-N 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
- 125000004463 2,4-dimethyl-thiazol-5-yl group Chemical group CC=1SC(=C(N1)C)* 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- LSZMVESSGLHDJE-UHFFFAOYSA-N 2-bromo-4-methylpyridine Chemical compound CC1=CC=NC(Br)=C1 LSZMVESSGLHDJE-UHFFFAOYSA-N 0.000 description 1
- LJASZNNBVOTAAN-UHFFFAOYSA-N 2-bromo-5-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(Br)C(C=O)=C1 LJASZNNBVOTAAN-UHFFFAOYSA-N 0.000 description 1
- WKIVBBWLRIFGHF-UHFFFAOYSA-N 2-chloro-3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1Cl WKIVBBWLRIFGHF-UHFFFAOYSA-N 0.000 description 1
- VFVHWCKUHAEDMY-UHFFFAOYSA-N 2-chloro-5-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(Cl)C(C=O)=C1 VFVHWCKUHAEDMY-UHFFFAOYSA-N 0.000 description 1
- RBGDLYUEXLWQBZ-UHFFFAOYSA-N 2-chlorobenzamide Chemical compound NC(=O)C1=CC=CC=C1Cl RBGDLYUEXLWQBZ-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- AAKQPKLNAOFUBB-UHFFFAOYSA-N 2-methoxy-3-nitrobenzaldehyde Chemical compound COC1=C(C=O)C=CC=C1[N+]([O-])=O AAKQPKLNAOFUBB-UHFFFAOYSA-N 0.000 description 1
- YWVSKFXYEWMHEO-UHFFFAOYSA-N 2-methoxy-5-nitrobenzaldehyde Chemical compound COC1=CC=C([N+]([O-])=O)C=C1C=O YWVSKFXYEWMHEO-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- ATLCWADLCUCTLL-UHFFFAOYSA-N 2-methyl-3-nitrobenzaldehyde Chemical compound CC1=C(C=O)C=CC=C1[N+]([O-])=O ATLCWADLCUCTLL-UHFFFAOYSA-N 0.000 description 1
- JLFWTLNLOSUFMU-UHFFFAOYSA-N 2-methyl-5-nitrobenzaldehyde Chemical compound CC1=CC=C([N+]([O-])=O)C=C1C=O JLFWTLNLOSUFMU-UHFFFAOYSA-N 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
- FMZJIXNDAVBBIK-UHFFFAOYSA-N 3-(chloromethyl)-5-methoxypyridine Chemical compound COC1=CN=CC(CCl)=C1 FMZJIXNDAVBBIK-UHFFFAOYSA-N 0.000 description 1
- OUDCOMBHRXKPIJ-UHFFFAOYSA-N 3-bromo-5-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC(Br)=CC(C=O)=C1 OUDCOMBHRXKPIJ-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- XZFQLZGPDRXXHV-UHFFFAOYSA-N 3-methoxy-5-nitrobenzaldehyde Chemical compound COC1=CC(C=O)=CC([N+]([O-])=O)=C1 XZFQLZGPDRXXHV-UHFFFAOYSA-N 0.000 description 1
- ZETIVVHRRQLWFW-UHFFFAOYSA-N 3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1 ZETIVVHRRQLWFW-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- LFIWXXXFJFOECP-UHFFFAOYSA-N 4-(aminomethyl)benzonitrile Chemical compound NCC1=CC=C(C#N)C=C1 LFIWXXXFJFOECP-UHFFFAOYSA-N 0.000 description 1
- PDONIKHDXYHTLS-UHFFFAOYSA-N 4-bromothiophene-2-carbaldehyde Chemical compound BrC1=CSC(C=O)=C1 PDONIKHDXYHTLS-UHFFFAOYSA-N 0.000 description 1
- HETBKLHJEWXWBM-UHFFFAOYSA-N 4-chloro-3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC(C=O)=CC=C1Cl HETBKLHJEWXWBM-UHFFFAOYSA-N 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- NZLNQSUMFSPISS-UHFFFAOYSA-N 4-chloropyridine-2-carbaldehyde Chemical compound ClC1=CC=NC(C=O)=C1 NZLNQSUMFSPISS-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- PQNRTCSIGGYXNB-UHFFFAOYSA-N 4-ethyl-3-nitrobenzaldehyde Chemical compound CCC1=CC=C(C=O)C=C1[N+]([O-])=O PQNRTCSIGGYXNB-UHFFFAOYSA-N 0.000 description 1
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
- VNDHYTGVCGVETQ-UHFFFAOYSA-N 4-fluorobenzamide Chemical compound NC(=O)C1=CC=C(F)C=C1 VNDHYTGVCGVETQ-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YTCRQCGRYCKYNO-UHFFFAOYSA-N 4-methoxy-3-nitrobenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1[N+]([O-])=O YTCRQCGRYCKYNO-UHFFFAOYSA-N 0.000 description 1
- KHWGAWBXQOKXIJ-UHFFFAOYSA-N 4-methyl-3-nitrobenzaldehyde Chemical compound CC1=CC=C(C=O)C=C1[N+]([O-])=O KHWGAWBXQOKXIJ-UHFFFAOYSA-N 0.000 description 1
- QTHQRNWVCRIQCR-UHFFFAOYSA-N 5-[(2-methylpropan-2-yl)oxycarbonylamino]pyridine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=C(C(O)=O)N=C1 QTHQRNWVCRIQCR-UHFFFAOYSA-N 0.000 description 1
- NGUVGKAEOFPLDT-UHFFFAOYSA-N 5-bromopyridine-3-carbaldehyde Chemical compound BrC1=CN=CC(C=O)=C1 NGUVGKAEOFPLDT-UHFFFAOYSA-N 0.000 description 1
- ZKLBPUYMTHPNOQ-UHFFFAOYSA-N 5-bromothiophene-3-carbaldehyde Chemical compound BrC1=CC(C=O)=CS1 ZKLBPUYMTHPNOQ-UHFFFAOYSA-N 0.000 description 1
- XJWUHOHPZSEMAG-UHFFFAOYSA-N 5-fluoro-N-[3-[[4-[methyl(2-methylpropyl)carbamoyl]piperidin-1-yl]methyl]phenyl]pyridine-3-carboxamide Chemical compound C1CC(C(=O)N(C)CC(C)C)CCN1CC1=CC=CC(NC(=O)C=2C=C(F)C=NC=2)=C1 XJWUHOHPZSEMAG-UHFFFAOYSA-N 0.000 description 1
- CWKOQDDWKWTOCF-UHFFFAOYSA-N 5-fluoropyridine-2-carboxamide Chemical compound NC(=O)C1=CC=C(F)C=N1 CWKOQDDWKWTOCF-UHFFFAOYSA-N 0.000 description 1
- QWFHFNGMCPMOCD-UHFFFAOYSA-N 6-bromopyridine-2-carbaldehyde Chemical compound BrC1=CC=CC(C=O)=N1 QWFHFNGMCPMOCD-UHFFFAOYSA-N 0.000 description 1
- DUKKRSPKJMHASP-UHFFFAOYSA-N 6-chloropyrimidin-4-amine Chemical compound NC1=CC(Cl)=NC=N1 DUKKRSPKJMHASP-UHFFFAOYSA-N 0.000 description 1
- VTNQPKFIQCLBDU-UHFFFAOYSA-N Acetochlor Chemical compound CCOCN(C(=O)CCl)C1=C(C)C=CC=C1CC VTNQPKFIQCLBDU-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101710098272 C-X-C motif chemokine 11 Proteins 0.000 description 1
- YQQODTYLJDDIGE-UHFFFAOYSA-N CC1=CC(=NO1)C(=O)NC=1C=C(CN2CCC(CC2)C(=O)O)C=CC1 Chemical group CC1=CC(=NO1)C(=O)NC=1C=C(CN2CCC(CC2)C(=O)O)C=CC1 YQQODTYLJDDIGE-UHFFFAOYSA-N 0.000 description 1
- 102000004497 CCR2 Receptors Human genes 0.000 description 1
- 108010017312 CCR2 Receptors Proteins 0.000 description 1
- FLCNFTKZLQQZGG-UHFFFAOYSA-N CCc1cc(N)cc(CN2CCC(CC2)C(=O)NC(C)(C)C)c1 Chemical compound CCc1cc(N)cc(CN2CCC(CC2)C(=O)NC(C)(C)C)c1 FLCNFTKZLQQZGG-UHFFFAOYSA-N 0.000 description 1
- UASZMLWEQGMGSZ-UHFFFAOYSA-N CNC(N)CC(C)C Chemical compound CNC(N)CC(C)C UASZMLWEQGMGSZ-UHFFFAOYSA-N 0.000 description 1
- 108010061299 CXCR4 Receptors Proteins 0.000 description 1
- MXTJAHAPTFMQSP-UHFFFAOYSA-N Cc1nc(CC(=O)Nc2cccc(CN3CCC(CC3)C(O)=O)c2)c(C)s1 Chemical compound Cc1nc(CC(=O)Nc2cccc(CN3CCC(CC3)C(O)=O)c2)c(C)s1 MXTJAHAPTFMQSP-UHFFFAOYSA-N 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
- 206010073073 Hepatobiliary cancer Diseases 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- JTKVXORXZGXJTI-UHFFFAOYSA-N N-cyclohexyl-1-[1-[3-[[2-methyl-5-(2-methylpropyl)pyrazole-3-carbonyl]amino]phenyl]ethyl]piperidine-4-carboxamide Chemical compound CN1N=C(CC(C)C)C=C1C(=O)NC1=CC=CC(C(C)N2CCC(CC2)C(=O)NC2CCCCC2)=C1 JTKVXORXZGXJTI-UHFFFAOYSA-N 0.000 description 1
- YKIWZTNMHNQQAA-UHFFFAOYSA-N N-cyclohexyl-1-[[3-[[2-(1-methylindol-3-yl)acetyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C12=CC=CC=C2N(C)C=C1CC(=O)NC(C=1)=CC=CC=1CN(CC1)CCC1C(=O)NC1CCCCC1 YKIWZTNMHNQQAA-UHFFFAOYSA-N 0.000 description 1
- XFZLHWUHNXKIQS-UHFFFAOYSA-N N-tert-butyl-1-[(2-ethyl-5-nitrophenyl)methyl]piperidine-4-carboxamide Chemical compound CCc1ccc(cc1CN1CCC(CC1)C(=O)NC(C)(C)C)[N+]([O-])=O XFZLHWUHNXKIQS-UHFFFAOYSA-N 0.000 description 1
- JSMVHGYLRDCDEH-UHFFFAOYSA-N N-tert-butyl-1-[(3-ethyl-5-nitrophenyl)methyl]piperidine-4-carboxamide Chemical compound CCc1cc(CN2CCC(CC2)C(=O)NC(C)(C)C)cc(c1)[N+]([O-])=O JSMVHGYLRDCDEH-UHFFFAOYSA-N 0.000 description 1
- FERJDBABYXVGKJ-UHFFFAOYSA-N N-tert-butyl-1-[(4-ethyl-3-nitrophenyl)methyl]piperidine-4-carboxamide Chemical compound CCc1ccc(CN2CCC(CC2)C(=O)NC(C)(C)C)cc1[N+]([O-])=O FERJDBABYXVGKJ-UHFFFAOYSA-N 0.000 description 1
- LEJLLCFTLRUYNM-UHFFFAOYSA-N N-tert-butyl-1-[(4-methyl-3-nitrophenyl)methyl]piperidine-4-carboxamide Chemical compound C1=C([N+]([O-])=O)C(C)=CC=C1CN1CCC(C(=O)NC(C)(C)C)CC1 LEJLLCFTLRUYNM-UHFFFAOYSA-N 0.000 description 1
- APUZQTBXTGNHTM-UHFFFAOYSA-N N-tert-butyl-1-[[3-[[2-(2,6-dichlorophenyl)acetyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)CC=2C(=CC=CC=2Cl)Cl)=C1 APUZQTBXTGNHTM-UHFFFAOYSA-N 0.000 description 1
- AUBOSVZOUKPBHH-UHFFFAOYSA-N N-tert-butyl-1-[[3-[[2-(2-chloro-4-fluorophenyl)acetyl]amino]phenyl]methyl]pyrrolidine-3-carboxamide Chemical compound CC(C)(C)NC(=O)C1CCN(Cc2cccc(NC(=O)Cc3ccc(F)cc3Cl)c2)C1 AUBOSVZOUKPBHH-UHFFFAOYSA-N 0.000 description 1
- ZIPCMIYUHKOEDJ-UHFFFAOYSA-N N-tert-butyl-1-[[3-[[2-[2,3-dichloro-6-(trifluoromethyl)phenyl]acetyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)CC=2C(=CC=C(Cl)C=2Cl)C(F)(F)F)=C1 ZIPCMIYUHKOEDJ-UHFFFAOYSA-N 0.000 description 1
- XHDPTXMFMUYWCD-UHFFFAOYSA-N N-tert-butyl-1-[[5-[[2-(2-chlorophenyl)acetyl]amino]thiophen-3-yl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CSC(NC(=O)CC=2C(=CC=CC=2)Cl)=C1 XHDPTXMFMUYWCD-UHFFFAOYSA-N 0.000 description 1
- FLILLFLIAKEFQV-UHFFFAOYSA-N N-tert-butyl-4-methylpiperidine-4-carboxamide hydrochloride Chemical compound Cl.CC(C)(C)NC(=O)C1(C)CCNCC1 FLILLFLIAKEFQV-UHFFFAOYSA-N 0.000 description 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- MQTBAGAVFDZXKF-UHFFFAOYSA-N [2-fluoro-4-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=C(C(F)(F)F)C=C1F MQTBAGAVFDZXKF-UHFFFAOYSA-N 0.000 description 1
- 230000007495 abnormal renal function Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 125000005001 aminoaryl group Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004532 benzofuran-3-yl group Chemical group O1C=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- QDYBCIWLGJMJGO-UHFFFAOYSA-N dinitromethanone Chemical compound [O-][N+](=O)C(=O)[N+]([O-])=O QDYBCIWLGJMJGO-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003174 enzyme fragment complementation Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- MCRPKBUFXAKDKI-UHFFFAOYSA-N ethyl pyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC=C1 MCRPKBUFXAKDKI-UHFFFAOYSA-N 0.000 description 1
- PAVZHTXVORCEHP-UHFFFAOYSA-N ethylboronic acid Chemical compound CCB(O)O PAVZHTXVORCEHP-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- GFAUNYMRSKVDJL-UHFFFAOYSA-N formyl chloride Chemical compound ClC=O GFAUNYMRSKVDJL-UHFFFAOYSA-N 0.000 description 1
- 125000001634 furandiyl group Chemical group O1C(=C(C=C1)*)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000004254 isoquinolin-1-yl group Chemical group [H]C1=C([H])C2=C([H])C([H])=C([H])C([H])=C2C(*)=N1 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- VZDNXXPBYLGWOS-UHFFFAOYSA-N methyl 3-aminobenzoate Chemical compound COC(=O)C1=CC=CC(N)=C1 VZDNXXPBYLGWOS-UHFFFAOYSA-N 0.000 description 1
- BFCUJOACQSXTBK-UHFFFAOYSA-N methyl azepane-4-carboxylate Chemical compound COC(=O)C1CCCNCC1 BFCUJOACQSXTBK-UHFFFAOYSA-N 0.000 description 1
- RZVWBASHHLFBJF-UHFFFAOYSA-N methyl piperidine-4-carboxylate Chemical compound COC(=O)C1CCNCC1 RZVWBASHHLFBJF-UHFFFAOYSA-N 0.000 description 1
- KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical compound CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 208000015325 multicentric Castleman disease Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
- UDAFQFHDGYBHTH-UHFFFAOYSA-N n-cyclohexyl-4-fluoropiperidine-4-carboxamide Chemical compound C1CCCCC1NC(=O)C1(F)CCNCC1 UDAFQFHDGYBHTH-UHFFFAOYSA-N 0.000 description 1
- KAMSFGRHKUFJCR-UHFFFAOYSA-N n-cyclohexyl-4-fluoropiperidine-4-carboxamide;hydrochloride Chemical compound Cl.C1CCCCC1NC(=O)C1(F)CCNCC1 KAMSFGRHKUFJCR-UHFFFAOYSA-N 0.000 description 1
- HSIWOXHWBJQTBP-UHFFFAOYSA-N n-cyclohexyl-4-methylpiperidine-4-carboxamide Chemical compound C1CCCCC1NC(=O)C1(C)CCNCC1 HSIWOXHWBJQTBP-UHFFFAOYSA-N 0.000 description 1
- WJXILHPPCMZNEF-UHFFFAOYSA-N n-cyclopropylpiperidine-4-carboxamide Chemical compound C1CNCCC1C(=O)NC1CC1 WJXILHPPCMZNEF-UHFFFAOYSA-N 0.000 description 1
- PESSDZSCDXYWIQ-UHFFFAOYSA-N n-cyclopropylpiperidine-4-carboxamide;hydrochloride Chemical compound Cl.C1CNCCC1C(=O)NC1CC1 PESSDZSCDXYWIQ-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- RPMICCWYOQJLNG-UHFFFAOYSA-N n-methyl-n-(2-methylpropyl)-1-[(3-nitrophenyl)methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)N(C)CC(C)C)CCN1CC1=CC=CC([N+]([O-])=O)=C1 RPMICCWYOQJLNG-UHFFFAOYSA-N 0.000 description 1
- HPAHOCMVEBYDRY-UHFFFAOYSA-N n-methyl-n-(2-methylpropyl)piperidine-4-carboxamide Chemical compound CC(C)CN(C)C(=O)C1CCNCC1 HPAHOCMVEBYDRY-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- NABSKEUDNDPCFE-UHFFFAOYSA-N n-tert-butyl-1-[(2-methoxy-3-nitrophenyl)methyl]piperidine-4-carboxamide Chemical compound C1=CC=C([N+]([O-])=O)C(OC)=C1CN1CCC(C(=O)NC(C)(C)C)CC1 NABSKEUDNDPCFE-UHFFFAOYSA-N 0.000 description 1
- GXHVUOZICBGHBQ-UHFFFAOYSA-N n-tert-butyl-1-[(2-methoxy-5-nitrophenyl)methyl]piperidine-4-carboxamide Chemical compound COC1=CC=C([N+]([O-])=O)C=C1CN1CCC(C(=O)NC(C)(C)C)CC1 GXHVUOZICBGHBQ-UHFFFAOYSA-N 0.000 description 1
- QTHULGODYCSILM-UHFFFAOYSA-N n-tert-butyl-1-[(2-methyl-3-nitrophenyl)methyl]piperidine-4-carboxamide Chemical compound C1=CC=C([N+]([O-])=O)C(C)=C1CN1CCC(C(=O)NC(C)(C)C)CC1 QTHULGODYCSILM-UHFFFAOYSA-N 0.000 description 1
- MNVWCJVSZKCLHC-UHFFFAOYSA-N n-tert-butyl-1-[(2-methyl-5-nitrophenyl)methyl]piperidine-4-carboxamide Chemical compound CC1=CC=C([N+]([O-])=O)C=C1CN1CCC(C(=O)NC(C)(C)C)CC1 MNVWCJVSZKCLHC-UHFFFAOYSA-N 0.000 description 1
- WMLUEQTUICBLDF-UHFFFAOYSA-N n-tert-butyl-1-[(3-methoxy-5-nitrophenyl)methyl]piperidine-4-carboxamide Chemical compound [O-][N+](=O)C1=CC(OC)=CC(CN2CCC(CC2)C(=O)NC(C)(C)C)=C1 WMLUEQTUICBLDF-UHFFFAOYSA-N 0.000 description 1
- GLAZCWVAMNDFHR-UHFFFAOYSA-N n-tert-butyl-1-[(4-methoxy-3-nitrophenyl)methyl]piperidine-4-carboxamide Chemical compound C1=C([N+]([O-])=O)C(OC)=CC=C1CN1CCC(C(=O)NC(C)(C)C)CC1 GLAZCWVAMNDFHR-UHFFFAOYSA-N 0.000 description 1
- OSOQJBCTUHQVMP-UHFFFAOYSA-N n-tert-butyl-1-[[3-[[2-(2-chlorophenyl)-2-hydroxyacetyl]amino]phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC(C)(C)C)CCN1CC1=CC=CC(NC(=O)C(O)C=2C(=CC=CC=2)Cl)=C1 OSOQJBCTUHQVMP-UHFFFAOYSA-N 0.000 description 1
- ULYPRPXLANHPJA-UHFFFAOYSA-N n-tert-butyl-4-fluoropiperidine-4-carboxamide Chemical compound CC(C)(C)NC(=O)C1(F)CCNCC1 ULYPRPXLANHPJA-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 208000023983 oral cavity neoplasm Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 150000002940 palladium Chemical class 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940100684 pentylamine Drugs 0.000 description 1
- LUYQYZLEHLTPBH-UHFFFAOYSA-N perfluorobutanesulfonyl fluoride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)S(F)(=O)=O LUYQYZLEHLTPBH-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 description 1
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- VZMVGGAQYQVROP-UHFFFAOYSA-N tert-butyl n-(3-methylphenyl)carbamate Chemical compound CC1=CC=CC(NC(=O)OC(C)(C)C)=C1 VZMVGGAQYQVROP-UHFFFAOYSA-N 0.000 description 1
- OWLBQQTUOQLZST-UHFFFAOYSA-N tert-butyl n-[4-(hydroxymethyl)-1,3-thiazol-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=NC(CO)=CS1 OWLBQQTUOQLZST-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- WQMRAWFGWVTLHX-UHFFFAOYSA-N thiophen-2-yl carbonochloridate Chemical compound ClC(=O)OC1=CC=CS1 WQMRAWFGWVTLHX-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 150000003608 titanium Chemical class 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12173227 | 2012-06-22 | ||
| ??12173227.5 | 2012-06-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201402546A TW201402546A (zh) | 2014-01-16 |
| TWI623522B true TWI623522B (zh) | 2018-05-11 |
Family
ID=49117908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW102122237A TWI623522B (zh) | 2012-06-22 | 2013-06-21 | 1-[間-甲醯胺基(雜)芳基-甲基]-雜環-甲醯胺衍生物 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20130345199A1 (OSRAM) |
| EP (1) | EP2864315B1 (OSRAM) |
| JP (1) | JP6182602B2 (OSRAM) |
| KR (1) | KR102101047B1 (OSRAM) |
| CN (1) | CN104395302A (OSRAM) |
| AR (1) | AR091516A1 (OSRAM) |
| AU (1) | AU2013278873B2 (OSRAM) |
| BR (1) | BR112014031755A8 (OSRAM) |
| CA (1) | CA2875389C (OSRAM) |
| ES (1) | ES2768399T3 (OSRAM) |
| MX (1) | MX364610B (OSRAM) |
| RU (1) | RU2644761C2 (OSRAM) |
| TW (1) | TWI623522B (OSRAM) |
| WO (1) | WO2013190508A2 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR091516A1 (es) | 2012-06-22 | 2015-02-11 | Actelion Pharmaceuticals Ltd | Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida |
| UA118562C2 (uk) * | 2013-05-30 | 2019-02-11 | Ідорсія Фармасьютікалз Лтд | Модулятори рецептора cxcr7 |
| UA118034C2 (uk) * | 2013-11-14 | 2018-11-12 | Елі Ліллі Енд Компані | Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази |
| CN107001279B (zh) | 2014-12-01 | 2020-10-20 | 爱杜西亚药品有限公司 | Cxcr7受体调节剂 |
| LT3490986T (lt) | 2016-07-28 | 2022-02-10 | Idorsia Pharmaceuticals Ltd | Piperidino cxcr7 receptoriaus moduliatoriai |
| EP3609882B1 (en) | 2017-03-17 | 2022-07-13 | Cardio Therapeutics Pty Ltd | Heterocyclic inhibitors of pcsk9 |
| JP7076010B2 (ja) | 2018-01-26 | 2022-05-26 | イドーシア ファーマシューティカルズ リミテッド | (3s,4s)-1-シクロプロピルメチル-4-{[5-(2,4-ジフルオロ-フェニル)-イソオキサゾール-3-カルボニル]-アミノ}-ピペリジン-3-カルボン酸 (1-ピリミジン-2-イル-シクロプロピル)-アミドの結晶形 |
| RU2677268C9 (ru) * | 2018-06-15 | 2019-07-23 | Общество с ограниченной ответственностью "Научно-исследовательский институт ХимРар", (ООО "НИИ ХимРар") | Частичный агонист допаминовых D2/D3 рецепторов - метиламид 4-{ 2-[4-(2,3-дихлорфенил)-пиперазин-1-ил]-этил} -пиперидин-1-карбоновой кислоты, способы его получения (варианты) и применения |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008045564A2 (en) * | 2006-10-12 | 2008-04-17 | Epix Delaware, Inc. | Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1233818A (en) | 1981-03-09 | 1988-03-08 | David J. Gilman | Guanidine derivatives as histamine h-2 receptor antagonists |
| WO2004099200A1 (en) | 2003-05-12 | 2004-11-18 | Pfizer Products Inc. | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders |
| NZ552404A (en) * | 2004-06-17 | 2010-04-30 | Cytokinetics Inc | Compounds, compositions and methods |
| WO2006036527A1 (en) * | 2004-09-28 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Substituted dipiperdine ccr2 antagonists |
| WO2009076404A1 (en) | 2007-12-10 | 2009-06-18 | Epix Delaware, Inc. | Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor |
| JP5785089B2 (ja) * | 2008-11-04 | 2015-09-24 | ケモセントリックス,インコーポレイティド | Cxcr7の調節因子 |
| AR091516A1 (es) | 2012-06-22 | 2015-02-11 | Actelion Pharmaceuticals Ltd | Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida |
| UA118562C2 (uk) | 2013-05-30 | 2019-02-11 | Ідорсія Фармасьютікалз Лтд | Модулятори рецептора cxcr7 |
-
2013
- 2013-06-19 AR ARP130102184 patent/AR091516A1/es unknown
- 2013-06-21 WO PCT/IB2013/055095 patent/WO2013190508A2/en not_active Ceased
- 2013-06-21 MX MX2014015691A patent/MX364610B/es active IP Right Grant
- 2013-06-21 CA CA2875389A patent/CA2875389C/en active Active
- 2013-06-21 CN CN201380033015.1A patent/CN104395302A/zh active Pending
- 2013-06-21 AU AU2013278873A patent/AU2013278873B2/en not_active Ceased
- 2013-06-21 TW TW102122237A patent/TWI623522B/zh not_active IP Right Cessation
- 2013-06-21 US US13/923,981 patent/US20130345199A1/en not_active Abandoned
- 2013-06-21 ES ES13759008T patent/ES2768399T3/es active Active
- 2013-06-21 BR BR112014031755A patent/BR112014031755A8/pt not_active Application Discontinuation
- 2013-06-21 US US14/410,426 patent/US9428456B2/en not_active Expired - Fee Related
- 2013-06-21 EP EP13759008.9A patent/EP2864315B1/en active Active
- 2013-06-21 KR KR1020157001830A patent/KR102101047B1/ko not_active Expired - Fee Related
- 2013-06-21 JP JP2015517912A patent/JP6182602B2/ja not_active Expired - Fee Related
- 2013-06-21 RU RU2015101751A patent/RU2644761C2/ru not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008045564A2 (en) * | 2006-10-12 | 2008-04-17 | Epix Delaware, Inc. | Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6182602B2 (ja) | 2017-08-16 |
| MX364610B (es) | 2019-05-02 |
| RU2644761C2 (ru) | 2018-02-14 |
| RU2015101751A (ru) | 2016-08-10 |
| WO2013190508A3 (en) | 2014-03-13 |
| JP2015520224A (ja) | 2015-07-16 |
| AR091516A1 (es) | 2015-02-11 |
| US20130345199A1 (en) | 2013-12-26 |
| CA2875389C (en) | 2020-09-15 |
| US9428456B2 (en) | 2016-08-30 |
| TW201402546A (zh) | 2014-01-16 |
| BR112014031755A2 (pt) | 2017-06-27 |
| AU2013278873B2 (en) | 2017-09-28 |
| KR20150023956A (ko) | 2015-03-05 |
| EP2864315A2 (en) | 2015-04-29 |
| CA2875389A1 (en) | 2013-12-27 |
| AU2013278873A1 (en) | 2015-02-12 |
| KR102101047B1 (ko) | 2020-04-16 |
| ES2768399T3 (es) | 2020-06-22 |
| BR112014031755A8 (pt) | 2017-12-26 |
| EP2864315B1 (en) | 2019-11-27 |
| WO2013190508A2 (en) | 2013-12-27 |
| MX2014015691A (es) | 2015-08-05 |
| CN104395302A (zh) | 2015-03-04 |
| US20150336893A1 (en) | 2015-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI623522B (zh) | 1-[間-甲醯胺基(雜)芳基-甲基]-雜環-甲醯胺衍生物 | |
| CN105209468B (zh) | 取代的7‑氮杂二环化合物以及它们作为食欲素受体调节剂的用途 | |
| JP2020507582A (ja) | キナーゼ阻害剤としてのアミノトリアゾロピリジン | |
| WO2013099041A1 (ja) | 新規なニコチンアミド誘導体またはその塩 | |
| JP7599411B2 (ja) | 受容体相互作用タンパク質キナーゼ1阻害剤(ripk1)としての1h-インダゾールカルボキサミド | |
| CN101193867A (zh) | N取代的苯并咪唑基c-Kit抑制剂和苯并咪唑组合库 | |
| JP7600228B2 (ja) | キナーゼ阻害剤としてのインダゾールカルボキサミド | |
| CN105263924B (zh) | Cxcr7受体调节剂 | |
| JP2019521163A (ja) | 二環式プロリン化合物 | |
| CA2842976A1 (en) | Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands | |
| EP3083597B1 (en) | Fluoromethyl-substituted pyrrole carboxamides as cav2.2 calcium channel blockers | |
| CN103153957B (zh) | N-吡啶-3-基或n-吡嗪-2-基甲酰胺类 | |
| US9562036B2 (en) | Fluoromethyl-substituted pyrrole carboxamides as CaV2.2 calcium channel blockers | |
| KR20100119789A (ko) | 2-아미노퀴놀린 | |
| EP3130589A1 (en) | Heterocyclic aza compounds | |
| HK1231465B (zh) | 可用作cb2激动剂的吡啶-2-酰胺类 | |
| HK1195911B (en) | Novel nicotinamide derivative or salt thereof | |
| HK1195911A (en) | Novel nicotinamide derivative or salt thereof | |
| TW201245153A (en) | N-pyridin-3-yl or n-pyrazin-2-yl carboxamides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |